The effect of rocuronium, sugammadex, and their combination on cardiac muscle and diaphragmatic skeletal muscle cells
- 437 Downloads
Rocuronium has been associated with muscle weakness when administered in prolonged infusions. The effect of sugammadex and rocuronium together on muscle is unknown. In this study, we examined the effects of rocuronium and sugammadex, and the complex formed by these agents, on cardiac and diaphragmatic muscle cells.
Forty-two Sprague–Dawley male rats were divided into six groups. Group I received only rocuronium at a dose of 1 mg/kg and groups II and III received sugammadex alone at doses of 16 and 96 mg/kg, respectively. Groups IV and V received 1 mg/kg rocuronium plus 16 mg/kg sugammadex and 1 mg/kg rocuronium plus 96 mg/kg sugammadex, respectively. Group six was the control group and received only 0.9 % NaCl without any drug.
Histopathological examination demonstrated that rocuronium and high doses of sugammadex accumulated in both cardiac and diaphragm muscle tissues. We also observed intense edema and degeneration in diaphragmatic and myocardial cells when the rocuronium-sugammadex complex was used. Rocuronium and sugammadex remain in the circulation for a long time and they may cause skeletal muscle myopathy, vacuolization, pyknotic nuclear clumps, and hypertrophy, and weaken the muscle fibers.
Rocuronium, sugammadex, and rocuronium–sugammadex complexes cause histopathological changes and immunoreactivity to calcineurin in muscle cells.
KeywordsSugammadex Muscle Diaphragmatic muscle cell Calcineurin Rat
- 3.Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Eng. 2002;41:266–70.Google Scholar
- 10.Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, Palin R, Prosser A, Rees DC, Rosair GM, Stevenson D, Tarver GJ, Zhang MQ. Cyclodextrin derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure–activity relationships. J Med Chem. 2002;45:1806–16.PubMedCrossRefGoogle Scholar
- 14.Peeters PA, van den Heuvel MW, van Heumen E, et al. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig. 2010;30:867–74.PubMedGoogle Scholar
- 15.Rex C, Bergner UA, Pühringer FK. Sugammadex: a selective relaxant-binding agent providing rapid reversal. Curr Opin Anesthesiol. 2010;23:461–5.Google Scholar
- 19.Johnson-Delaney C. Small rodents, exotic animal companion medicine. In: Handbook for veterinarians, Zoological Education Network 1996. p. 18–9.Google Scholar
- 21.Inder WJ, Jang C, Obeyesekere VR, Alford FP. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1—implications for steroid-induced myopathy. Clin Endocrinol (Oxf). 2010;73(1):126–32.Google Scholar